Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255151 · ClinicalTrials.gov registry record · Phase 3
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
A Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 451
- Enrollment target
- 20
- Study locations
NCT00255151: Completed Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, sponsored by Takeda.
NCT00255151 is a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic that has completed, run by Takeda. The registered enrollment target is 451 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00255151, a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 451 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
Primary Outcome
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexlansoprazole MR
Study Locations (20)
California
- - Azusa
- - Carmichael
- - Cypress
- - Fresno
- - Los Angeles
- - Modesto
- - Newport Beach
- - Oakland
- - Orange
- - San Diego
- - Santa Maria
Alabama
- - Anniston
- - Hueytown
- - Huntsville
- - Tallassee
- - Tuscaloosa
Arkansas
- - Little Rock
- - North Little Rock
Arizona
- - Tucson
Colorado
- - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00255151 record still lists
NCT00255151 is an interventional study that assigns participants to a tested intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Esophagitis, Reflux appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00255151 names 20 study sites across 5 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00255151 about?
NCT00255151 is a clinical study titled "Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis". The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
What is the current status of trial NCT00255151?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 451 participants. The study started on 2006-01. Estimated completion is 2006-11.
What conditions does trial NCT00255151 study?
This clinical trial studies the following conditions: Esophagitis, Reflux, Esophagitis, Peptic.
What interventions are being tested in trial NCT00255151?
The interventions under investigation include: Placebo (DRUG), Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00255151?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00255151 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagitis, Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00255151's enrollment target sits among peer trials
451 836th of 2000 higher than 1,164 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia